Primary Antibiotic Resistance of Helicobacter Pylori in Chinese Patients: a Multiregion Prospective 7-Year Study.
Y. Xie,D. Liu,Y. Wang,Z. Zeng,Z. Zhang,H. Lu,J. Xu,Y. Du,Y. Li,J. Wang,S. Xu,Y. Chen,C. Lan,H. Cheng,M. Jiang,L. Zhang,N. Lu
DOI: https://doi.org/10.1016/j.cmi.2017.11.010
IF: 13.31
2018-01-01
Clinical Microbiology and Infection
Abstract:Objectives: To explore the characteristics of Helicobacter pylori resistance in China and the association between antibiotic resistance and several clinical factors. Methods: H. pylori strains were collected from patients in 13 provinces or cities in China between 2010 and 2016. Demographic data including type of disease, geographic area, age, gender and isolation year were collected to analyse their association with antibiotic resistance. Antibiotic resistance was detected using the Etest test and the Kirby-Bauer disc diffusion method. Results: H. pylori were successfully cultured from 1117 patients. The prevalence of metronidazole, clarithromycin (CLA), azithromycin, levofloxacin (LEV), moxifloxacin, amoxicillin (AMO), tetracycline and rifampicin resistance was 78.2, 22.1, 23.3, 19.2, 17.2, 3.4, 1.(and 1.5%, respectively. No resistance to furazolidone was observed. The resistance rates to LEV and moxifloxacin were higher in strains isolated from patients with gastritis compared to those with duodenal ulcer and among women. Compared to patients >= 40 years old, younger patients exhibited lower resistance rates to CLA, azithromycin, LEV and moxifloxacin. The resistance rates to CLA and AMO were higher in strains isolated more recently, and we also found that the prevalence of resistance to metronidazole, CLA, azithromycin and AMO were significantly different among different regions of China. Conclusions: The resistance rates to metronidazole, CLA and LEV were high in China. Patient age, gender, disease and location were associated with the resistance of H. pylori to some antibiotics. Furazolidone, AMO and tetracycline are better choices for H. pylori treatment in China. (C) 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.